US 12,006,311 B2
Compounds for use in preventing or treating cancer
Josep Roma Castanyer, Barcelona (ES); Marta Pascual Gilabert, Barcelona (ES); José Sánchez De Toledo Codina, Barcelona (ES); Soledad Gallego Melcón, Barcelona (ES); Patricia Zarzosa Martínez, Barcelona (ES); Javier Alonso Fernández, Mollet del Valles (ES); Sergio Pérez Ozcáriz, Mollet del Valles (ES); Cristina López Gómez, Mollet del Valles (ES); and Josep Castells Boliart, Mollet del Valles (ES)
Assigned to FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA, Barcelona (ES); and INSTITUT UNIV. DE CIÈNCIA I TECNOLOGIA, S. A., Mollet del Valles (ES)
Appl. No. 17/256,837
Filed by FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERCA, Barcelona (ES); and INSTITUT UNIV. DE CIÈNCIA I TECNOLOGIA, S. A., Mollet del Valles (ES)
PCT Filed Jul. 1, 2019, PCT No. PCT/EP2019/067557
§ 371(c)(1), (2) Date Dec. 29, 2020,
PCT Pub. No. WO2020/002701, PCT Pub. Date Jan. 2, 2020.
Claims priority of application No. 18382485 (EP), filed on Jun. 29, 2018.
Prior Publication US 2021/0230150 A1, Jul. 29, 2021
Int. Cl. C07D 409/14 (2006.01); A61K 45/06 (2006.01); A61P 35/04 (2006.01)
CPC C07D 409/14 (2013.01) [A61K 45/06 (2013.01); A61P 35/04 (2018.01)] 15 Claims
OG exemplary drawing
 
1. A compound selected from the group consisting of:
4,5-Dichloro-N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)thiophene-2-sulfonamide;
N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3,5-dimethylisoxazole-4-sulfonamide;
N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)benzo[d][1,3] dioxole-5-sulfonamide;
N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-5-(pyridin-2-yl)thiophene-2-sulfonamide;
N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)benzofuran-2-sulfonamide;
4,5-Dichloro-N-(cyanomethyl)-N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)thiophene-2-sulfonamide;
Ethyl N-(benzo[d][1,3]dioxol-5-ylsulfonyl)-N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)glycinate;
N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-N-(2-morpholino-2-oxoethyl)benzo[d][1,3]dioxole-5-sulfonamide;
2-((4,5-dichloro-N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)thiophene)-2-sulfonamido)acetamide; and
Ethyl N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-N-((5-(pyridin-2-yl)thiophen-2-yl)sulfonyl)glycinate;
or a salt thereof.